Sax Wealth Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 378.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,828 shares of the company’s stock after buying an additional 7,775 shares during the quarter. Sax Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,745,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. increased its stake in Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after buying an additional 3,358,478 shares during the period. GQG Partners LLC grew its position in Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Johnson & Johnson by 37.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after acquiring an additional 1,805,632 shares in the last quarter. Swiss National Bank grew its position in Johnson & Johnson by 14.0% in the first quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock worth $2,020,868,000 after acquiring an additional 1,396,500 shares in the last quarter. Finally, Bridgewater Associates LP grew its position in Johnson & Johnson by 40.3% in the first quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock worth $770,065,000 after acquiring an additional 1,247,260 shares in the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts have commented on the stock. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Raymond James decreased their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Bank of America decreased their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Sanford C. Bernstein decreased their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Finally, Atlantic Securities decreased their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.
Johnson & Johnson Price Performance
Shares of Johnson & Johnson stock opened at $177.01 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The firm has a fifty day moving average price of $168.60 and a two-hundred day moving average price of $171.32. The company has a market cap of $462.79 billion, a PE ratio of 24.65, a price-to-earnings-growth ratio of 3.50 and a beta of 0.57.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same period in the prior year, the firm earned $2.60 EPS. The business’s revenue was up 1.9% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.04 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.
Johnson & Johnson declared that its board has approved a share buyback plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.